One of the first reports describing the use of recombinant aequorin as a reporter molecule in a bioluminometric nucleic acid hybridization assay was in 1996. 1 Microtiter wells were coated with anti-digoxigenin antibody. The target DNA was hybridized simultaneously with an immobilized digoxigenin-labeled capture probe and a biotinylated detection probe. The hybrids were determined using an aequorin-streptavidin conjugate followed by the measurement of luminescence in the presence of excess Ca 21 (Figure 9.1). The linearity of the assay was in the range 0.1-200 pM (5 amol well À1 to 10 fmol well À1) and the S/B ratio at 0.1 pM (5 amol well À1) was 5.3. A configuration in which the aequorinstreptavidin conjugate was replaced by a preformed complex of biotinylated aequorin to streptavidin resulted in equivalent signals and detectability. An advantage of using the preformed complex is that it was conveniently prepared by simply mixing the two components (streptavidin and biotinylated aequorin), thus providing a practical alternative to the use of aequorin-streptavidin conjugates prepared by covalent crosslinking techniques. The aequorin-biotin and the aequorin-streptavidin conjugates in this study were obtained commercially (the same group later reported the construction of a plasmid suitable for bacterial expression of in vivo-biotinylated aequorin, facilitating further the development of highly sensitive hybridization assays, 2 as well as a method for